Indirect comparison of ixekizumab versus risankizumab for up to 12 weeks of treatment in patients with moderate-to-severe psoriasis

被引：0
|
作者：
Gottlieb, Alice B. [1 ]
Ramot, Yuval [2 ]
Smith, Saxon D. [3 ]
Saure, Daniel [4 ]
Schuster, Christopher [5 ]
Schacht, Alexander [4 ]
Thaci, Diamant [6 ]
机构：
[1] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA
[2] Hadassah Hebrew Univ, Med Ctr, Dept Dermatol, Jerusalem, Israel
[3] Univ Sydney, Sydney Med Sch, Discipline Dermatol, Sydney, NSW, Australia
[4] Lilly Deutschland GmbH, Bad Homburg, Germany
[5] Eli Lilly GmbH, Vienna, Austria
[6] Univ Hosp Schleswig Holstein, Inst & Comprehens Ctr Inflammat Med, Campus Lubeck, Lubeck, Germany
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2019年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
9775
引用
收藏
页码：AB226 / AB226
页数：1
相关论文
共 50 条
  • [1] Indirect comparison of ixekizumab versus tildrakizumab for up to 12 weeks of treatment in patients with moderate-to-severe psoriasis
    Gottlieb, Alice
    Saure, Daniel
    Wilhelm, Stefan
    Dossenbach, Martin
    Thaci, Diamant
    Smith, Saxon D.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB82 - AB82
  • [2] Matching-adjusted indirect treatment comparison of guselkumab and ixekizumab in patients with moderate-to-severe psoriasis
    Varu, Abhishek
    Cameron, Chris
    Diels, Joris
    Hutton, Brian
    McElligott, Sean
    Schubert, Agata
    van Sanden, Suzy
    Villacorta, Reggie
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB187 - AB187
  • [3] Ixekizumab versus FAEs and methotrexate in treatment of nail psoriasis in patients with moderate-to-severe psoriasis
    Augustin, Matthias
    Mrowietz, Ulrich
    Willsmann-Theis, Dagmar
    Gerdes, Sascha
    Fotiou, Konstantinos
    Schuster, Christopher
    Mert, Can
    Holzkaemper, Thorsten
    Behrens, Frank
    Pinter, Andreas
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2024,
  • [4] Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
    Papp, Kim A.
    Blauvelt, Andrew
    Bukhalo, Michael
    Gooderham, Melinda
    Krueger, James
    Lacour, Jean-Philippe
    Menter, Alan
    Philipp, Sandra
    Sofen, Howard
    Tyring, Stephen
    Berner, Beate R.
    Visvanathan, Sudha
    Pamulapati, Chandrasena
    Bennett, Nathan
    Flack, Mary
    Scholl, Paul
    Padula, Steven J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (16): : 1551 - 1560
  • [5] Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis
    Fioranelli, Massimo
    Roccia, Maria Grazia
    Lotti, Torello
    [J]. DERMATOLOGIC THERAPY, 2017, 30 (05)
  • [6] High and durable clearance through 52 weeks of risankizumab treatment in patients with moderate-to-severe plaque psoriasis
    Gooderham, M.
    Lebwohl, M.
    Gordon, K.
    Wu, T.
    Photowala, H.
    Bachelez, H.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 20 - 20
  • [7] High and durable clearance through 52 weeks of risankizumab treatment in patients with moderate-to-severe plaque psoriasis
    Gooderham, M.
    Lebwohl, M.
    Gordon, K.
    Wu, T.
    Photowala, H.
    Bachelez, H.
    [J]. EXPERIMENTAL DERMATOLOGY, 2023, 32 (04) : E30 - E31
  • [8] Risankizumab in moderate-to-severe plaque psoriasis
    Serrano, Linda
    Maloney, Victoria
    Gordon, Kenneth B.
    [J]. IMMUNOTHERAPY, 2019, 11 (16) : 1357 - 1370
  • [9] Safety in numbers: risankizumab for moderate-to-severe psoriasis
    Mirali, S.
    Fabusiwa, K.
    Linos, E.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (03) : 394 - 395
  • [10] Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: the first septennium
    Carmona-Rocha, Elena
    Puig, Lluis
    [J]. IMMUNOTHERAPY, 2023, 15 (15) : 1209 - 1225
12345